



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/18, C07K 14/50, 14/51, C12N 5/06	A1	(11) International Publication Number: WO 98/33515 (43) International Publication Date: 6 August 1998 (06.08.98)
(21) International Application Number: PCT/US98/02143 (22) International Filing Date: 4 February 1998 (04.02.98) (30) Priority Data: 60/037,119 5 February 1997 (05.02.97) US (71) Applicant: CASE WESTERN RESERVE UNIVERSITY [US/US]; 10900 Euclid Avenue, Cleveland, OH 44106-7080 (US). (72) Inventors: DENNIS, James, E.; 1593 Maple Road, Cleveland, OH 44118 (US). CAPLAN, Arnold, I.; 1300 Oakridge Drive, Cleveland Heights, OH 44121 (US). (74) Agents: HERRON, Charles, J. et al.; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ 07068 (US).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: STIMULATORY EFFECTS OF bFGF AND BMP-2 ON OSTEOGENIC DIFFERENTIATION OF MESENCHYMAL STEM CELLS		
(57) Abstract <p>Bone marrow stroma contains multipotential mesenchymal progenitor cells which can differentiate into osteoblastic cells; we refer to these cells as mesenchymal stem cells (MSCs). Basic fibroblast growth factor (bFGF) and bone morphogenetic protein-2(BMP-2) have been implicated in the osteogenic regulatory process by virtue of their mitogenic and differentiation activities, respectively. This study examines and compares the effects of bFGF and BMP-2 on dexamethasone (Dex)-dependent <i>in vitro</i> osteogenic differentiation of rat marrow-derived MSCs. A 6-day exposure to bFGF markedly stimulated cell growth and induced osteoblastic differentiation as shown by osteocalcin mRNA expression (day 14), bone nodule formation (day 18), and calcium deposition (day 18). These results indicate that bFGF enhances both mitogenic activity and osteogenic development of Dex-treated marrow MSCs. In contrast, BMP-2 did not induce an osteogenesis as strongly as bFGF. Thus, exposure to BMP-2 slightly increased bone nodule number and calcium content compared with the control. Exposure of MSCs to both BMP-2 and bFGF induced expression of osteocalcin mRNA and mineralizing bone-like nodules as early as day 11, and resulted in enhancement of bone formation more markedly than either factor alone. Consistent with these results, porous calcium phosphate ceramic cubes implanted <i>in vitro</i>, which were loaded with MSCs pre-exposed to both bFGF and BMP-2, showed higher histologic score for bone formation than those with MSCs pre-exposed to either bFGF or BMP-2. These data indicate that combined treatment with bFGF or BMP-2 synergistically enhances the osteogenic potency of bFGF in rat marrow MSC culture.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**STIMULATORY EFFECTS OF bFGF AND BMP-2 ON
OSTEOGENIC DIFFERENTIATION OF MESENCHYMAL STEM CELLS**

This work was supported in part by grants from the NIH. The U.S. government has certain rights in the invention.

Bone marrow is a complex tissue composed of hematopoietic and mesenchymal elements. The stroma of bone marrow is composed of a highly organized network of mesenchymal cells and extracellular matrix that provides structural and functional support for hematopoiesis. Within the marrow stromal cell population, mesenchymal progenitor cells exist which are capable of differentiating into several different mesenchymal tissues including bone and cartilage (1); we refer to these cells as mesenchymal stem cells (MSCs) (2, 3). Production of a bone-like mineralized tissue from bone marrow-derived mesenchymal cells has been demonstrated *in vivo* in diffusion chambers and porous calcium phosphate ceramics loaded with whole bone marrow or culture-adherent marrow cells and has also been observed *in vitro*, where bone-like tissue is synthesized by bone marrow-derived mesenchymal cells cultured in medium containing ascorbic acid, glycerophosphate and the synthetic glucocorticoid dexamethasone (Dex) (4-10). These results support the concept that marrow contains osteoprogenitor cells that are involved in bone remodeling and repair in adults.

Potential regulators of osteogenic differentiation from marrow-derived mesenchymal progenitor cells include both soluble and bone matrix-derived factors. Numerous factors are known which exert modulatory effects on cells with the osteoblastic phenotype. Among them, basic fibroblast growth factor (bFGF) is a strong mitogen for bone-derived cells (11-13) and bone morphogenic protein-2 (BMP-2) has been shown to be an active inducer of osteoblastic differentiation of both immature osteoblasts and less committed cells (14,15). Recent studies indicate that bFGF also induces bone formation by stimulating proliferation and differentiation of mesenchymal osteoprogenitor cells when administered systemically or locally to fracture sites (16,17). However, the effects of this factor on the osteogenic differentiation of bone marrow-derived MSCs are still controversial. Pitaru *et al.* (18,19) reported that bFGF stimulates osteogenic differentiation of Dex-treated bone marrow MSCs as evidenced by enhanced alkaline phosphatase (ALP) activity, osteocalcin production and bone nodule formation. In another study, bFGF induced proliferation, but reversibly inhibited the differentiation of bone marrow-derived osteoblastic progenitors (20). With regard to BMP-2, a number of studies indicate that this factor can up-regulate markers for the mature osteoblastic phenotype, such as ALP activity, collagen synthesis and osteocalcin expression (21-23). In addition, studies have shown that BMP-2 increases expression of osteoblast indicators from pluripotent stem cell cultures, which suggests that BMP-2 regulates the entrance of uncommitted cells into specific differentiation pathways (14,23).

Our laboratory has developed an *in vitro* culture technique for isolation, expansion and maintenance of the bone marrow-derived MSCs from various animal species (2,3,6-8,24).

Summary Of The Invention

The study that resulted in the present invention examined the combined effects of bFGF and BMP-2 on the proliferation and osteogenic differentiation of rat bone marrow-derived MSCs in our above-referenced culture system. Combined treatment with the mitogenic factor bFGF and differentiation factor BMP-2

stimulated osteogenesis more than exposure to each factor alone. The results provide a rational basis for their clinical application.

In one aspect, the invention provides a method of enhancing osteogenic differentiation of culture-expanded mesenchymal stem cells. The method comprises exposing such mesenchymal stem cells to both bFGF and a member of the TGF- β superfamily. This method particularly comprises successive exposure of mesenchymal stem cells to BMP-2 in combination with dexamethasone followed by contact of the cells with bFGF. Alternatively, the invention provides for concurrent contact of the cells with BMP-2 and bFGF.

In another aspect, the invention provides a method of accelerating osteogenic differentiation of culture-expanded mesenchymal stem cells. The method comprises exposing such mesenchymal stem cells to both bFGF and a member of the TGF- β superfamily. This method particularly comprises successive exposure of mesenchymal stem cells to BMP-2 in combination with dexamethasone followed by contact of the cells with bFGF. Alternatively, it is consistent with the invention to provide for concurrent contact of the cells with BMP-2 and bFGF.

The invention further provides a composition comprising the combination of human isolated, culture-expanded mesenchymal stem cells with BMP-2, an osteoinductive agent such as dexamethasone and bFGF.

Brief Description of the Drawings

Figure 1. DNA content of MSC cultures on day 7. Rat marrow MSCs were plated at a density of 5×10^3 cells/cm² in 24-well culture plates and treated for 6 days with no factors (control); BMP-2 (50 ng/ml); bFGF (2.5 ng/ml); and a combination of bFGF and BMP-2 in complete medium containing 10% FBS and 10^{-7} M Dex. On day 7, cultures were washed and then assayed for DNA content. Each measurement is the mean of quadruplicate cultures. Standard deviation (SD) of the mean is shown by vertical bars. Mean \pm SD of DNA content of untreated cultures on day 1 was 0.09 ± 0.01 μ g. A significant difference ($p < 0.05$) in comparison with the control value is indicated by an asterisk (*).

Figure 2. Treatment with bFGF and BMP-2 stimulates expression of osteocalcin mRNA in rat marrow MSC cultures. Rat marrow MSCs were plated at a density of 5×10^3 cells/cm² in 24-well culture plates and treated for 6 days with no factors (control, C); BMP-2 (50 ng/ml) (B); bFGF (2.5 ng/ml) (F); and a combination of bFGF and BMP-2 (FB) in complete medium containing 10% FBS and 10^{-7} M Dex. Thereafter, the medium was replaced with "osteogenic" medium (complete medium plus 10^{-7} M Dex, ascorbate (50 µg/ml) and β-glycerophosphate (10 mM). RNA was extracted on days 7, 11, and 14. Separate PCRs were done for actin and osteocalcin. Reaction products specific for actin (227 bp) and osteocalcin (414 bp) were visualized on ethidium bromide-stained agarose gels. The first lane on the left represents molecular weight markers of *HaeIII* restriction fragments of φX174 DNA.

Figure 3. Phase contrast micrographs of MSC cultures on day 11 (x100): control (a); BMP-2 (50 ng/ml) (b); bFGF (2.5 ng/ml) (c); and combined treatment with bFGF and BMP-2 (d). The cultures were prepared as described in the above description for Fig. 2. Note the mineralizing early bone nodules (n) present in the cultures treated with bFGF and BMP-2. An uncalcified small cell colony (c) is also observed in the bFGF-treated culture.

Figure 4. Photographs of von Kossa-stained MSC cultures on day 18 (x1.3): control (a), BMP-2 (50 ng/ml) (b); bFGF (c) (2.5 ng/ml); and combined treatment with bFGF and BMP-2 (d). The cultures were prepared as described in the above description for Fig. 2.

Figure 5. Calcium content of control cultures (C) and cultures treated with 2.5 ng/ml bFGF (F), 12.5, 25, and 50 ng/ml BMP-2 (B12.5, B25, and B50, respectively), and both 2.5 ng/ml bFGF and 12.5, 25, or 50 ng/ml BMP-2 (F+B12.5, F+B25, and F+B50, respectively) on days 14 and 18. The cultures were prepared as described in the above description for Fig. 2. In parallel with calcium assay, DNA content of matching samples was also determined. All data are expressed per 0.1 µg of DNA. Each measurement is the mean of data obtained from three separate experiments. Standard deviation (SD) of the mean is shown by

vertical bars. Significant differences are presented as *, ↑ and ↓ ($p < 0.05$) in comparison with the values for the control, 50 ng/ml BMP-2, and bFGF, respectively.

Figure 6. Effects of early (Days 1-4) and/or late (Days 4-7) addition of 2.5 ng/ml bFGF and 25 ng/ml BMP-2 on osteogenic differentiation of rat marrow MSCs. Factors were administered on day 1 to Dex-treated MSC cultures and removed on day 4 or added on day 4 and removed on day 7 or both. The cultures were prepared as described in the legend for Fig. 2. Calcium content was measured on day 18. In parallel with this assay, DNA content of matching samples was also determined. All data are expressed per 0.1 μ g of DNA. Each measurement is the mean of triplicate cultures. Standard deviation (SD) of the mean is shown by transverse bars.

Figure 7. Histologic features of a section of a ceramic cube loaded with MSCs exposed to both bFGF and BMP-2 (x100). Cubes were harvested from host rats 6 weeks postimplantation. After fixation and decalcification, histologic sections were prepared and stained with Mallory-Heidenhain. The new bone (b) is formed along the walls of individual pores. Decalcified ceramic material (c) appears as acellular space stained lightly.

Detailed Description of the Preferred Embodiments

Materials

A selected lot of fetal bovine serum (FBS) (24), Dulbecco's modified Eagle's medium containing low glucose (DMEM-LG), trypsin-EDTA, antibiotic-antimycotic solution (penicillin, streptomycin and fungizon), Superscript II reverse transcriptase, dNTP mix, dithiothreitol, 5X first strand buffer, oligo(dt)₁₂₋₁₈, RNase H, 10X polymerase chain reaction (PCR) buffer, MgCl₂, Taq DNA polymerase, and *Hae* III restriction fragments of ϕ X174 DNA were purchased from Gibco BRL (Gaithersburg, MD). Tyrode's salts, dexamethasone (Dex), calf thymus DNA, 3, 5-diaminobenzoic acid dihydrochloride (DABA), and calcium assay kit were obtained from Sigma Chemical Co. (St. Louis, MO). Fibronectin was purchased from Collaborative Biomedical (Bedford, MA). Calf serum was procured from Hyclone

Laboratories (Logan, UT). Total RNA isolation kit was purchased from Qiagen Inc. (Chatsworth, CA). Recombinant bovine basic fibroblast growth factor (bFGF) was purchased from Boehringer Mannheim (Indianapolis, IN). Recombinant human bone morphogenic protein-2 (BMP-2) was a generous gift from Genetics Institute (Cambridge, MA). Falcon plasticware, including 24- and 96-well culture plates, was purchased from Becton-Dickinson Labware (Franklin Lakes, IN). Porous calcium phosphate ceramic cubes were generously provided by Zimmer/Bristol Myers Squibb (Warsaw, IN). Fisher 344 rats were purchased from Charles River Laboratory (Wilmington, MA) and 10% neutral buffered formalin was from Fisher Scientific (Orangetown, NY).

Marrow MSC culture

MSC cultures were prepared from the bone marrow of femurs and tibias harvested from 2-month-old male F344 rats by a technique previously described (25). Briefly, the bones were cleaned of adherent soft tissue, the epiphyses removed with a rongeur, and the marrow harvested by inserting a syringe needle (18-gauge) into one end of the bone and flushing with complete medium (DMEM-LG supplemented with antibiotic-antimycotic solution and 10% FBS) into a 60-mm culture dish. A cell suspension was obtained by drawing the marrow into syringes sequentially three times through needles of decreasing size (gauge 18, 20, 22, respectively). The cells were then centrifuged, counted, seeded at a density of 5×10^7 in 7 ml of complete medium per 100-mm culture dish, and cultured at 37°C in 95% humidified air and 5% CO₂. At 3 days after seeding, non-adherent cells were removed by changing the medium; thereafter, the medium was changed every 3-4 days.

After 12-14 days of primary culture, when large cell colonies developed on the dishes, the cells were liberated by exposure to 0.25% trypsin/1 mM EDTA for 5 minutes at 37°C, followed by the addition of one-half volume of calf serum to stop the reaction. The released cells were then centrifuged, resuspended in complete medium, and seeded at 5×10^3 cells/cm² in 24-well plates for biochemical and PCR analyses or in 100-mm culture dishes to generate cells for *in vivo* ceramic cube assays. On day 1 following plating, the attached cells were exposed to bFGF and/or BMP-2.

Exposure of the marrow MSC cultures to bFGF and BMP-2

The MSC cultures were exposed continuously to 2.5 ng/ml recombinant bovine bFGF and/or recombinant human BMP-2 at concentrations up to 100 ng/ml in 0.5 ml of complete medium in the presence of 10^{-7} M Dex for 6 days. Optimal dose of bFGF, determined by measuring DNA content and ALP activity at various time points, plateaued at a dose of 2.5 ng/ml. Control cultures were maintained without added bFGF or BMP-2, but in the presence of 10^{-7} M Dex. The medium was changed once on day 4 and replaced with medium containing fresh growth factors. On day 7, the cultures were rinsed with Tyrode's balanced salt solution, and the medium was replaced with "osteogenic" medium (complete medium plus 10^{-7} M Dex, 50 μ g/ml ascorbate and 10 mM β -glycerophosphate) to induce bone formation (26). Freshly prepared ascorbate was added to the cultures every other day. Cultured cells were harvested for PCR and biochemical analyses on days 7, 11, 14, and 18. All biochemical assays were carried out with at least triplicate wells.

Measurement of DNA content

DNA content of the cultures was assayed with the techniques described by Gillery *et al.* (27). Briefly, the cells in each well of 24-well plates were rinsed with Tyrode's solution and then fixed with ethanol. Freshly prepared DABA solution (80 mg/ml, 0.2 ml) was added to each well. The standard curve was obtained by performing the DABA reaction in culture wells containing various concentrations of calf thymus DNA. The plates were then incubated for 45 minutes at 60°C. The reaction between DABA and DNA was stabilized by adding 1.5 ml of 1 M HCl to every well and the intensity of fluorescence was measured at 420 nm excitation and 490 nm emission in a spectrophotofluorometer (American Instrument Co., Silver Spring, MA). The DNA content was determined from a standard curve.

Total RNA extraction, cDNA synthesis, and RT-PCR analysis

Total RNA was extracted with a commercial kit following the manufacturer's instructions. The purity and amount of isolated RNA were assessed by spectrophotometric measurement at 260 and 280 nm. Total RNA (1.5 μ g) was reverse transcribed to cDNA at 42°C for 50 minutes in a volume of 20 μ l containing

the following reagents: 0.5 mM dNTP mix, 10 mM dithiothreitol; 0.5 μ g oligo(dT)₁₂₋₁₈, 1X first strand buffer (5X = 250 mM Tris, pH 8.3, 375 mM KCl and 15 mM MgCl₂) and 20 U of Superscript II (RNase H-free reverse transcriptase). After terminating the reaction at 70°C for 15 minutes, 1 U of RNase H was added to the reaction mixture, which was incubated at 37°C for 10 minutes to remove the RNA.

Aliquots of the total cDNA were diluted 1: 50,000 and then amplified in 50 μ l of a PCR reaction mixture which contained 20 pmol of primer sets for osteocalcin or actin, 1X PCR buffer (10X = 200 mM Tris, pH 8.4, and 500 mM KCl), 0.2 mM dNTP mix, 1.5 mM MgCl₂, and 2.5 U of *Taq* DNA polymerase. Primers for osteocalcin were purchased from Operon Technologies Inc. (Alameda, CA) which synthesized them based on the sequences described by Arakt *et al.* (28). Primers for actin were kindly provided by Dr. E. M. Greenfield (Dept. of Orthopedics, Case Western Reserve University, Cleveland, OH). Amplifications were performed in a Robocycler Gradient 40 temperature cycler (Stratagene Cloning Systems, La Jolla, CA). DNA amplification included an initial denaturation at 94°C for 2 minutes, followed by 35 cycles of denaturation at 94°C for 1 minute, annealing at 58°C (osteocalcin primers) or 60°C (actin primers) for 1 minute, and extension at 72°C for 1 minute. The final cycle included 5 minutes for extension.

Abundance of PCR products was analyzed by electrophoresis of samples in 2% agarose gels stained with ethidium bromide; *Hae* III restriction fragments of ϕ X174 DNA were used as molecular weight markers.

Bone nodule, assay

For quantification of bone nodule formation, the cultures were fixed with neutral buffered formalin and stained by the method of von Kossa (26). Freshly prepared 2% silver nitrate was added to the plates (0.5 ml/well), which were incubated in the dark for 10 minutes. The plates were rinsed with distilled water and then exposed to bright light for 15 minutes. The reaction was terminated by rinsing thoroughly with distilled water. The strongly stained nodules were counted under a dissecting microscope.

Determination of calcium content

After fixation with neutral buffered formalin, 0.5 ml of 0.6 N HCl was added to each well to decalcify the cultures (29). After 24 hours, the HCl supernatant was recovered, appropriately diluted with 0.6 N HCl, and transferred into wells of a 96-well plate. Thereafter, reagents from a commercial calcium assay kit were added to the samples and the absorbance read at 575 nm with a model 2550 EIA reader (Bio-Rad Labs, Hercules, CA); the concentration of the reaction product was determined from a standard curve.

In vivo ceramic cube assay

The ceramic composite assay was performed to test the *in vivo* osteogenic potential of cultured cells (6-8,26). First passage cells exposed to test agents for 6 days were rinsed with Tyrode's solution, harvested by trypsinization, resuspended at 5×10^6 cells/ml in serum-free DMEM-LG medium, and placed in a 5-ml tube containing 3-mm porous calcium phosphate ceramic cubes precoated with fibronectin (7). After producing a slight vacuum to release airpockets from the ceramic cubes, the tubes were placed in a CO₂ incubator at 37°C for 2 hours to allow the cells to attach to the ceramic surface. The cubes were then implanted subcutaneously into syngeneic F344 male rats. The ceramics were harvested 6 weeks postimplantation, fixed in 10% neutral buffered formalin, and processed for routine histology. The entire sample was serially sectioned and every 7th and 8th sections were stained with Mallory-Heidenhain. Each stained section was examined and scored for bone on a grading scale of 0 to 4 as previously described (26). The scores of all sections were combined and divided by the number of sections graded to determine the overall score of each ceramic cube.

Statistical Analyses

The results obtained were expressed as the mean \pm SD (standard deviation of the mean) of triplicate or quadruplicate cultures. Differences between experimental groups were determined with Student's *t*-test. For analyses of histologic score, Kruskal-Wallis One Way Rank test was used. Differences at $P < 0.05$ were considered significant.

In pilot experiments, treatments with bFGF, BMP-2 and both factors did not induce bone nodule formation without Dex in the cultures. Therefore, the experiments reported here were performed with continuous exposure to Dex for the 17-day duration of the experiment.

Effects of bFGF, BMP-2, and their combined treatments on MSC growth

Marrow MSCs exposed to bFGF alone or in combination with 50 ng/ml BMP-2 showed an approximately 3-fold increase in DNA content compared with control cultures on day 7 (Fig. 1). There was no significant difference in DNA content between bFGF and bFGF+BMP-2-treated cultures. On the contrary, DNA content in the cultures treated with BMP-2 alone was the same as that of the control; similar results were obtained from the assays at later time points (data not shown). These results indicate that bFGF stimulates the proliferation of marrow-derived MSCs in culture in the presence of Dex, whereas BMP-2 does not stimulate a mitogenic response.

Effects of bFGF, BMP-2 and their combined treatments on the osteogenic development of cultured marrow MSCs

For comparison of osteogenic activities of bFGF, BMP-2 and bFGF+BMP-2, osteocalcin mRNA expression, bone nodule formation, and calcium deposition were assessed as late markers of mature osteoblast functions.

Osteocalcin, mRNA expression: RT-PCR analyses revealed that combined treatment with 2.5 ng/ml bFGF and 50 ng/ml BMP-2 induced early expression of osteocalcin mRNA on day 11, while treatment with bFGF alone produced a relatively weak expression (Fig. 2). On day 14, strong mRNA expression was detected in bFGF- and bFGF+BMP-2-treated cultures. In contrast, BMP-2-treated cultures had only low but detectable levels of osteocalcin mRNA even at this late time.

Bone nodule formation: Consistent with early expression of osteocalcin mRNA, mineralizing bone-like nodules appeared in bFGF+BMP-2-treated cultures

on day 11 (Fig. 3). In bFGF-treated cultures, uncalcified cell groupings were observed. On day 18, cultures treated with bFGF alone or in combination with 50 ng/ml BMP-2 developed a substantial number of calcified bone nodules (Fig. 4). In contrast, the number of bone nodules in BMP-2-treated cultures was much smaller than that in bFGF-treated cultures; the size of the nodules in BMP-2-treated cultures was similar to that in bFGF-treated cultures.

Calcium deposition: To quantify the amount of bone-like tissue developed in the cultures, calcium content was measured (Fig. 5). A 6-day pretreatment with bFGF significantly increased calcium content on day 14 and induced a marked elevation on day 18. Continuous 17-day exposure to bFGF did not further enhance the calcium accumulation (data not shown). Treatment with 50 ng/ml BMP-2 also induced a significant elevation of this parameter on day 18. However, the calcium content of BMP-2-treated cultures was about half of that of bFGF-treated cultures. Furthermore, 100 ng/ml BMP-2, continuous 17 day-exposure to 50 ng/ml BMP-2, or increasing MSC number at plating did not augment the calcium deposition and bone nodule formation (data not shown). Combined treatment with bFGF and BMP-2 induced an early increase in calcium deposition on day 14 and resulted in the highest levels of its accumulation on day 18. The maximum synergistic effect was observed in cultures exposed to 2.5 ng/ml bFGF in combination with 25 ng/ml BMP-2, which alone did not elevate the level of calcium deposition over control cultures. Calcium content of 14-day cultures treated with both bFGF and 25 ng/ml BMP-2 was 3-fold greater than that of bFGF-treated cultures. In comparison to cultures treated with 25 ng/ml BMP-2, exposure to both bFGF and BMP-2 showed a 20-fold increase. Thus, these results demonstrate that treatment with bFGF or BMP-2 alone stimulates Dex-dependent osteogenic differentiation of rat marrow MSCs, but the potency of BMP-2 is not as high as that of bFGF in this MSC culture system. Data further indicate that combined treatment with bFGF and BMP-2 enhanced *in vitro* osteogenesis more markedly than either factor alone.

Early or late exposure to bFGF and BMP-2: To further define the exposure timing for BMP-2 and bFGF in MSC differentiation, factors were added to cultures in the presence of Dex either "early" (Days 1-4) or "late" (Days 4-7), as illustrated

in Fig. 6, and calcium content was measured on day 18. As for the experiment in Fig. 5, 6-day exposure to 25 ng/ml BMP-2 alone was ineffective at increasing calcium deposition. Early 3-day treatment with bFGF increased calcium content more effectively than late 3-day treatment, which indicates that bFGF acts at an early stage of MSC cultures. Treatment with bFGF at the early stage followed by BMP-2 at the late time resulted in a greater increase in calcium deposition than continuous treatment with bFGF alone. Early bFGF treatment followed by late BMP-2 treatment resulted in calcium accumulation equivalent to that in cultures treated for the entire 6 days with both bFGF and BMP-2. Treatments in the reverse order caused a small calcium accumulation. These data show that bFGF pretreatment followed by BMP-2 exposure was the most effective at stimulating *in vitro* Dex-dependent osteogenesis of marrow MSCs.

In vivo osteogenic potential of marrow MSCs exposed to bFGF, BMP-2 or both factors in vitro

To examine their *in vivo* osteogenic potential, samples of MSCs pretreated with bFGF, BMP-2 or bFGF+BMP-2 were loaded into porous ceramic cubes and then implanted into syngeneic rats. Six weeks postimplantation, cubes were harvested and assessed for bone formation by histologic scoring. The results are set forth in Table 1.

Table 1

In vivo bone formation in ceramics loaded with MSCs exposed to bFGF and/or BMP-2

<i>Treatments*</i>	<i>Histologic score</i>	<i>No. of bone-positive ceramics (% Incidence)</i>
Control	0.24 ± 0.27	4 (50)
BMP-2	0.08 ± 0.19	2 (25)
bFGF	0.55 ± 0.35 ↑	7 (87.5)
bFGF + BMP-2	0.87 ± 0.29 ↑ ↓	8 (100)

Data are expressed as the mean \pm SD.

*Four cubes per animal were harvested 6 weeks after implantation. Data obtained from a total of 8 rats (8 cubes per treatment) in two independent experiments were combined and analyzed.

$\uparrow P < 0.05$ compared with the control and $\downarrow P < 0.05$ compared with bFGF treatment. Significance determined with the Kruskal-Wallis One Way Rank test.

As presented in Table 1, bFGF and bFGF+BMP-2 treatments resulted in a high incidence of bone-positive ceramics and the histologic scores were significantly higher than those of the control. Cells pretreated with BMP-2 showed very low osteogenic potential. In good agreement with *in vitro* data, combined exposure to BMP-2 and bFGF increased the histologic score significantly in comparison with bFGF treatment.

Figure 7 shows a representative section from the histologic analysis of a cube loaded with MSCs treated with bFGF+BMP-2. New woven bone, in which many osteocytes were embedded, was formed along the walls of individual pores within the cubes. The morphologic appearance of the bone which formed was histologically identical for all cubes seeded with the control cells or cells pre-treated with bFGF, BMP-2, or both factors. These results indicate that bFGF and bFGF+BMP-2 treatments enhance the *in vivo* osteogenic potential of marrow MSCs.

The studies described above demonstrate that bFGF is a mitogen for rat marrow MSCs and, in the presence of Dex, stimulates their osteogenic differentiation. The MSCs were cultured with Dex-supplemented medium, since it was reported to be essential for induction of *in vitro* osteogenesis in various culture systems (9, 10). Treatment with bFGF in the absence of Dex results in no osteogenesis. In the presence of Dex, an initial 3 day-exposure to bFGF is more effective at inducing bone formation than if bFGF is added later (Fig.6). This suggests that bFGF acts on early Dex-committed osteoprogenitor cells and/or uncommitted MSCs responsive to Dex at an earlier differentiation stage. Thus, the

effects of bFGF, are probably mediated predominantly by stimulation and proliferation of osteoprogenitor cells to form a larger pool of cells capable of responding to Dex. Thereafter, the Dex must drive these cells to terminal differentiation, which results in a significant enhancement of bone formation. In addition, based on a cascade theory of bone formation (22) and a report that bFGF stimulates TGF- β 1 gene expression in osteoblast-like cells (30), we believe that TGF- β and proteins of the BMP family are produced by the MSCs treated with bFGF+Dex and exert their osteogenic effects on MSCs in an autocrine and/or paracrine manner. Investigation of the expression of these factors and their receptors during the osteogenic differentiation of MSCs exposed to bFGF and Dex supports this proposition.

BMP-2 slightly induces bone nodule formation and calcium deposition compared with the control cultures. A weak osteogenic potential of BMP-2-treated MSCs was further confirmed with the *in vivo* ceramic cube assay. Recently, Rickard *et al.* (21) demonstrated that BMP-2 (50 ng/ml) acted synergistically with Dex to increase ALP activity and vitamin D-induced mRNA expression for type I collagen and osteocalcin in rat primary stromal cell cultures. However, they did not assess actual *in vitro* bone formation represented by bone nodule formation and calcium deposition as presented here. Moreover, the methods of cell preparation were different from ours. They added BMP-2 to whole marrow primary cultures containing adherent and non-adherent cell populations for days 1-3 and then re-exposed the adherent cell fraction to BMP-2 after removing the non-adherent cells. In this study, only culture-expanded, first passage MSCs were used. In other culture systems with mouse marrow stromal cell lines and fetal rat calvarial cells, BMP-2 (25-100 ng/ml) greatly stimulated ALP activity, osteocalcin production, and bone nodule formation (31-33). Discrepancies between our results and those of others may be due to differences in the differentiation stage of the cells used, the age of the donor animals, and species differences.

BMP-2 was also reported to stimulate adipogenic and chondrogenic differentiation in cultures of a murine mesenchymal pluripotential line C3H10T1/2 (23). However, after a 6-day treatment of MSCs with 50 and 100 ng/ml BMP-2,

or during continuous exposure, there was no enhanced adipogenic differentiation by day 18 compared with the control cultures, and no chondrocytes appeared by histologic examination of the cultures.

Surprisingly, combined exposure of MSC cultures to bFGF and BMP-2 markedly enhances bone formation *in vitro* and *in vivo* compared to exposure to bFGF alone. Moreover, the early appearance of mineralizing nodules and mRNA for osteocalcin (day 11) and an early increase in calcium deposition (day 14) indicate that osteogenic differentiation is accelerated in bFGF+BMP-2-treated cultures. These data demonstrate that Dex-dependent osteogenesis of marrow MSCs is enhanced by bFGF and BMP-2 co-treatment. As presented in Fig. 6, the successive exposure of MSCs to BMP-2 followed by bFGF results in an increase in calcium deposition equivalent to the combined treatment and was much more effective than when the factors were presented in the reverse order. This result indicates that early treatment with bFGF and Dex induced a large number of BMP-2-responsive osteoprogenitor cells and thereafter these cells are driven to differentiate into fully mature osteoblasts by BMP-2 and Dex treatments. It is likely that a 3-day treatment with bFGF and Dex increases the number of osteoprogenitor cells which have already expressed BMP-2 receptors and/or induces the expression of receptors on them for exogenous as well as endogenous BMP-2. An enhancement of bone formation by co-treatment with bFGF and BMP-2 can be explained by this mechanism.

It is widely accepted that the bone formation process is controlled sequentially and cooperatively by many growth factors (22). Therefore, it is unlikely that any single factor controls the entire sequence of differentiation from osteoprogenitor cell to mature osteoblast. The present study revealed that the mitogenic factor, bFGF, and differentiation factor, BMP-2, exhibit a strong synergism during relatively early stages of differentiation in rat marrow MSC cultures and result in enhancement of osteogenesis *in vitro* and *in vivo*. Each of these factors has been demonstrated to stimulate bone formation in normal and wounded animal models, such as those with a bone fracture and bone defect (16,17,34). Thus, it is reasonable to expect that combined treatment with bFGF and BMP-2 would provide more effective cell- and

growth factor-based therapies for repair of bone wounds or reversal of bone loss in osteoporosis.

Cited Literature

1. Owen M, 1988, Marrow stromal stem cells. J Cell Sci Suppl **10**:63-76.
2. Caplan AI 1991 Mesenchymal stem cells. J Orthop Res **9**:641-650.
3. Caplan AI 1993 The mesengenic process. Clinics in Plastic Surg **21**:429-435.
4. Ashton BA, Allen TD, Howlett CR, Eaglesom CC, Hattori A, Owen M 1980 Formation of bone and cartilage by marrow stromal cells in diffusion chambers *in vivo*. Clin Orthop **151**:294-307.
5. Friedenstein AJ, Chailakhyan RK, Gerasimov U 1987 Bone marrow osteogenic cells: *in vitro* cultivation and transplantation in diffusion chambers. Cell Tissue Kinet **20**:263-272.
6. Goshima J, Goldberg VM, Caplan AI 1991 The osteogenic potential of culture-expanded rat marrow mesenchymal cells assayed *in vivo* in calcium phosphate ceramics blocks. Clin Orthop **262**:298-311.
7. Dennis JE, Haynesworth SE, Young RG, Caplan AI 1992 Osteogenesis in marrow-derived mesenchymal cell porous ceramic composites transplanted subcutaneously: effect of fibronectin and laminin on cell retention and rate of osteogenic expression. Cell Transplant **1**:23-32.
8. Haynesworth SE, Goshima J, Goldberg VM, Caplan AI 1992 Characterization of cells with osteogenic potential from human marrow. Bone **13**:81-88.
9. Maniopoulos C, Sodek J, Melcher AH 1988 Bone formation *in vitro* by stromal cells obtained from bone marrow of young adult rats. Cell Tissue Res **254**:317-330.

10. Herbertson A, Aubin JE 1995 Dexamethasone alters the subpopulation make-up of rat bone marrow stromal cell cultures. *J Bone Miner Res* **10**:285-294.
11. Globus RK, Patterson-Buckendahl P, Gospodarowicz D 1988 Regulation of bovine bone cell proliferation by fibroblast growth factor and transforming growth factor β . *Endocrinology* **123**:98-105.
12. Rodan SB, Wesolowski G, Thomas KA, Yoon K, Rodan GA 1989 Effects of acidic and basic fibroblast growth factors on osteoblastic cells. *Conn Tissue Res* **20**:283-288.
13. Cannalis E, Centrella M, MacCarthy TL 1988 Effects of basic fibroblast growth factor on bone formation *in vitro*. *J Clin Invest* **81**:1572-1577.
14. Katagiri T, Yamaguchi A, Ikeda T, Yoshiki S, Wozney JM, Rosen V, Wang EA, Tanaka H, Omura S, Suda T 1990 The nonosteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2. *Biochem Biophys Res Commun* **172**:295-299.
15. Yamaguchi A, Katagiri T, Ikeda T, Wozney JM, Rosen V, Wang EA, Kahn AJ, Suda T, Yoshiki S 1991 Recombinant human bone morphogenetic protein-2 stimulates osteoblast maturation and inhibits myogenic differentiation *in vitro*. *J Cell Biol* **113**:681-687.
16. Kawaguchi H, Kurokawa T, Hanada K, Hiyama Y, Tamura M, Ogata E, Matsumoto T 1994 Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin-diabetic rats. *Endocrinology* **135**:774-781.
17. Nakamura T, Hanada K, Tamura M, Shibanushi T, Nigi H, Tagawa M, Fukumoto S, Matsumoto T 1995 Stimulation of endosteal bone formation by

systemic injection of recombinant basic fibroblast growth factor in rats. *Endocrinology* **136**:1276-1284.

18. Pitaru S, Kotev-Emeth S, Noff D, Kaffuler S, Savion N 1993 Effect of basic fibroblast growth factor on the growth and differentiation of adult stromal bone marrow cells: Enhanced development of mineralized bonelike tissue in culture. *J Bone Miner Res* **8**:919-929.
19. Savion N, Pri-Chen S, Pitaru S 1996 bFGF enhances the growth and the expression of osteogenic phenotype of dexamethasone treated human bone marrow derived bone-like cells in culture. *J Bone Miner Res* **11**:S347 (Abstract).
20. Majors AE, Muschler GF 1996 Basic FGF enhances proliferation and reversibly inhibits differentiation of osteoblastic progenitors. *Transaction of the Orth Res Soc* **21**:113 (Abstract).
21. Rickard DJ, Sullivan TA, Shenker BJ, Leboy PS, Kazhdan I 1994 Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. *Dev Biol* **161**:218-228.
22. Mundy GR, Boyce B, Hughes D, Wright K, Bonewald L, Dallas S, Harris S, Ghosh-Choudhury N, Chen D, Dunstan C, Izbicka E, Yoneda T 1995 The effects of cytokines and growth factors on osteoblastic cells. *Bone* **17**:71S-75S.
23. Wang EA, Israel DI, Kelly S, Luxenberg DP 1993 Bone morphogenetic protein-2 causes commitment and differentiation in C3HIOT1/2 and 3T3 cells. *Growth Factors* **9**:57-51.

24. Lennon DP, Haynesworth SE, Bruder SP, Jaiswal N, Caplan AI 1996 Human and animal mesenchymal progenitor cells from bone marrow: Identification of serum for optimal selection and proliferation. *In Vitro Cell Dev Biol* in press.
25. Lennon DP, Haynesworth SE, Young RG, Dennis JE, Caplan AI 1995 1995 A chemically defined medium supports *in vitro* proliferation and maintains the osteochondral potential of rat marrow-derived mesenchymal stem cells. *Exp Cell Res* **219**:211-222.
26. Cassiede P, Dennis JE, Ma F, Caplan AI 1996 Osteochondrogenic potential of marrow mesenchymal progenitor cells exposed to TGF-01 or PDGF-BB as assayed *in vivo* and *in vitro*. *J Bone Miner Res* **11**:1264-1273.
27. Gillery P, Bonnet A, Borel J-P 1993 A fluorometric deoxyribonucleic acid assay for tridimensional lattice cultures of fibroblasts. *Anal Biochem* **210**:374-377.
28. Araki N, Robinson FD, Nishimoto SK 1993 Rapid and sensitive method for quantitation of bone gla protein mRNA using competitive polymerase chain reaction. *J Bone Miner Res* **8**:313-322.
29. Iwasaki M, Nakahara H, Nakase T, Kimura T, Takaoka K, Caplan AI, Ono K 1994 Bone morphogenetic protein 2 stimulates osteogenesis but does not affect chondrogenesis in osteochondrogenic differentiation of periosteum-derived cells. *J Bone Miner Res* **9**:1195-1204.
30. Noda M, Vogel R 1989 Fibroblast growth factor enhances type I transforming growth factor gene expression in osteoblast-like cells. *J Cell Biol* **109**:2529-2535.

31. Thies RS, Bauduy M, Ashton BA, Kurtzberg L, Wozney JM, Rosen V 1992 Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. *Endocrinology* **130**:1318-1324.
32. Hughes, FJ, Collyer J, Stanfield M, Goodman SA 1995 The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells *in vitro*. *Endocrinology* **136**:2671-2677.
33. Boden SD, McCuaig K, Hair G, Rachine M, Titus L, Wozney JM, Hanes MS 1996 Differential effects and glucocorticoid potentiation of bone morphogenetic protein action during rat osteoblast differentiation *in vitro*. *Endocrinology* **137**:3401-3407.
34. Linkhart TA, Mohan S, Baylink DJ 1996 Growth factors for bone growth and repair: IGF, TGF- β and BMP. *Bone* **19**:1S-12S.

What Is Claimed Is:

1. A method of enhancing osteogenic differentiation of mesenchymal stem cells, which method comprises exposing such mesenchymal stem cells to both bFGF and a member of the TGF- β superfamily.

2. The method of claim 1 which comprises successive exposure of mesenchymal stem cells to BMP-2 in combination with dexamethasone followed by contact of the cells with bFGF.

3. The method of claim 1 which comprises concurrent contact of the cells with BMP-2 and bFGF.

4. A method of accelerating osteogenic differentiation of mesenchymal stem cells, which method comprises exposing such mesenchymal stem cells to both bFGF and a member of the TGF- β superfamily.

5. The method of claim 4 which comprises successive exposure of mesenchymal stem cells to BMP-2 in combination with dexamethasone followed by contact of the cells with bFGF.


6. The method of claim 4 which comprises concurrent contact of the cells with BMP-2 and bFGF.

7. A composition comprising the combination of human isolated, culture-expanded mesenchymal stem cells with BMP-2 and an osteoinductive agent.

8. Thhe composition of claim 7 wherein the osteoinductive agent is elected from the group of dexamethasone and bFGF.

1/6

FIG. 1



2/6

FIG. 2




FIG. 7






FIG. 3A



FIG. 3B



FIG. 3C



FIG. 3D




FIG. 4A



FIG. 4B





FIG. 4C




FIG. 4D

FIG. 5



6/6

FIG. 6



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/02143

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/18; C07K 14/50, 14/51; C12N 5/06

US CL : 435/377; 424/198.1; 552/574

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/377; 424/198.1; 552/574

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAPLUS

search terms: mesenchymal stem cell, bmp, tgf-beta, fgf, dexamethasone, glucocorticoid

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,197,985 A (CAPLAN et al.) 30 March 1993, Abstract, column 1, line 58 to column 2, line 38, claims 1-15.	1-8
Y	CRABB et al. Synergistic effect of transforming growth factor-beta and fibroblast growth factor on DNA synthesis in chick growth plate chondrocytes. J. Bone. Min. Res. November 1990, Vol. 5, No. 11, pages 1105-1112, see especially paragraph bridging columns 1-2 on page 1105 through page 1106, column 1, full paragraph 2.	1, 4



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

12 APRIL 1998

Date of mailing of the international search report

01 JUN 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID S. ROMEO

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/02143

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NISWANDER et al. Mixed signals from the AER: FGF-4 and BMP-2 have opposite effects on limb growth. Prog. Clin. Biol. Res. 1993. Vol. 383B, pages 625-633, see especially page 628, full paragraph 2 through paragraph bridging pages 628-629, page 631, full paragraph 1.	2, 3, 5-8
Y	RICKARD et al. Induction of rapid osteoblast differentiation in rat bone marrow stromal cell cultures by dexamethasone and BMP-2. Dev. Biol. January 1994, Vol. 161, No. 1, pages 218-228, see especially page 218, Abstract.	2, 5, 7, 8